PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Ранг среди акций #1418
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Цена акции
$37.84
Рыночная капитализация
$15.65B
Изменение (1 день)
-4.42%
Изменение (1 год)
149.23%
Страна
TW
Торговля PharmaEssentia Corporation (6446)

Категория

Healthcare
EPS для PharmaEssentia Corporation (6446)
EPS по состоянию на June 2026 TTM: $0.63
Согласно последним финансовым отчетам и цене акций PharmaEssentia Corporation, текущий EPS компании (TTM) составляет $0.63. В конце 2023 EPS компании составлял $-0.06, меньше, чем показателю 2022 года, равному $-0.14.
История EPS компании PharmaEssentia Corporation с 2010 по 2026
EPS на конец каждого года
Год EPS Изменить
2026 (TTM) $0.63 153.00%
2024 $0.25 -534.22%
2023 $-0.06 -60.15%
2022 $-0.14 -59.50%
2021 $-0.35 37.91%
2020 $-0.25 119.47%
2019 $-0.12 -14.95%
2018 $-0.14 15.09%
2017 $-0.12 5.89%
2016 $-0.11 -6.67%
2015 $-0.12 -4.08%
2014 $-0.13 25.60%
2013 $-0.10 63.82%
2012 $-0.06 25.36%
2011 $-0.05 16.87%
2010 $-0.04 0.00%
EPS для аналогичных компаний или конкурентов